Cellular Immunotherapy to Target WT1, Survivin and TERT for AML is under clinical development by Boryung ViGenCell and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy to Target WT1, Survivin and TERT for AML’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cellular Immunotherapy to Target WT1, Survivin and TERT for AML overview

Cellular immunotherapy is under development for the treatment of relapsed or refractory acute myelocytic leukemia. It comprises of T cells which are modified to target Wilms tumor protein (WT1), survivin and telomerase reverse transcriptase (TERT) expressing cancer cells. It is administered through intravenous route.

Boryung ViGenCell overview

Boryung ViGenCell a healthcare company that engaged in the immune cell therapy services. The company is headquartered in Seoul, South Korea.

For a complete picture of Cellular Immunotherapy to Target WT1, Survivin and TERT for AML’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.